Table 2.
Patients | Sensitivity YJV | Sensitivity Ves v 5 | Sensitivity Ves v 5/Ves v 1 | Methoda | Remarks | Reference |
---|---|---|---|---|---|---|
100 | 91% (91)b | 89% (89) | n.d. | ADVIA Centaurd | [39] | |
91 | IC sIgE | 96% (87) | n.d. | |||
59 | 86% (51)b | 90% (53) | n.d. | ImmunoCAP | [40] | |
32 | IC sIgE | 94% (30) | n.d. | ms | ||
19 | IC sIgE | 95% (18) | n.d. | ds | ||
8 | IC neg.b | 63% (5) | n.d. | |||
22 | IC sIgE | n.s. | 100% (22) | ImmunoCAP | ms | [51] |
200 | IC sIgE | 85% (169) | 92% (184) | ImmunoCAP | ms | [43] |
163 | n.s. | 92% (150) | 96% (156) | ImmunoCAP | [50] | |
26 | IC neg.b | 65% (17) | 65% (17) | |||
308 | 83% (257)b | 90% (277) | 96% (296) | ImmunoCAP | [20••] | |
308 | 97% (298)c | 90% (277) | 96% (296) | |||
148 | 89% (131)b | 89% (131) | 94% (139) | ImmunoCAP | [42] | |
91 | IC sIgE | 90% (82) | 98% (89) | ms | ||
17 | IC neg.b | 71% (12) | 71% (12) | |||
170 | IC sIgE | 93% (158) | n.d. | ImmunoCAP | [41] | |
103 | IC sIgE | 92% (95) | n.d. | ms | ||
67 | IC sIgE | 94% (63) | n.d. | ds | ||
43 | IC sIgE | 98% (42) | n.d. | ImmunoCAP | [32••] | |
111 | 100% (111) | 87% (96) | 98% (109) | ImmunoCAP | [45] | |
111 | 98% (109) | 92% (102) | n.d. | Immulite | ||
110 | IC sIgE | 82% (90) | 90% (99) | ImmunoCAP | ms | [44] |
110 | IC sIgE | 93% (102) | 97% (107) | Immulite/ImmunoCAP | ms | |
25 | 92% (23)b | 92% (23) | 100% (25) | Immulite | [49] | |
49e | 88% (43)b | 86% (42) | 92% (45) |
n.d. not determined, n.s. not shown, IC sIgE sIgE to YJV ≥ 0.35 kUA/L was inclusion criterion, IC neg. sIgE to YJV < 0.35 kUA/L was inclusion criterion, ms yellow jacket venom-monosensitized, ds yellow jacket venom and honeybee venom-double-sensitized
aValues ≥ 0.35 kUA/L were considered positive
bYJV extract not spiked with Ves v 5 was used for measurement
cYJV extract spiked with Ves v 5 was used for measurement
dNo longer available
ePatients with mastocytosis and/or elevated baseline serum tryptase